- Home
- DGICB vs DNA Comparison
DGICB vs DNA Comparison
Compare DGICB & DNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DGICB | DNA |
|---|---|---|
| Founded | 1986 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 848.9M | 835.7M |
| IPO Year | 1995 | 2020 |
Fundamental Metrics
Financial Performance| Metric | DGICB | DNA |
|---|---|---|
| Price | $27.35 | $10.54 |
| Analyst Decision | | Sell |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | 1.5K | ★ 2.4M |
| Earning Date | 10-29-2026 | 11-05-2026 |
| Dividend Yield | ★ 2.56% | N/A |
| EPS Growth | N/A | ★ 46.49 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $978,014,322.00 | $170,155,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $13.05 |
| P/E Ratio | $8.06 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $15.10 | $5.37 |
| 52 Week High | $29.99 | $18.22 |
Technical Indicators
Market Signals| Indicator | DGICB | DNA |
|---|---|---|
| Relative Strength Index (RSI) | 67.15 | 48.85 |
| Support Level | $15.56 | $6.75 |
| Resistance Level | $27.61 | $13.97 |
| Average True Range (ATR) | 1.47 | 1.52 |
| MACD | 0.38 | -0.04 |
| Stochastic Oscillator | 100.00 | 29.96 |
Price Performance
Historical ComparisonAbout DGICB Donegal Group Inc. Class B
Donegal Group Inc is an insurance holding company whose insurance subsidiaries and affiliates offer property and casualty insurance in 21 Mid-Atlantic, Midwestern, Southern, and Southwestern states. It includes three segments: Investments Function, Commercial Lines of Insurance, and Personal Lines of Insurance. The majority of revenue is from the commercial Lines segment. The commercial Lines segment consists mainly of commercial automobile, commercial multi-peril, and workers' compensation policies.
About DNA Ginkgo Bioworks Holdings Inc.
Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering engaged in providing biological R&D services for customers across a range of industries and Biosecurity that provides services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment.